Tyra Biosciences, Inc.
For the period ended Mar 31, 2026. Filed May 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 13, 2026
TYRA$21.00-5.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Stockholders Equity
(in thousands, except share amounts)
| Common Stock · Additional Paid-In Capital · Accumulated Other Comprehensive Income · AccumulatedDeficit · Total Stockholders’ Equity | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balance at December 31, 2024 | 50,749,945 | $5 | $593,687 | $770 | $(251,311) | $343,151 |
| Issuance of common stock pursuant to pre-funded warrant exercise | 2,000,069 | — | — | — | — | — |
| Issuance of common stock under benefit plans | 335,626 | — | 2,187 | — | — | 2,187 |
| Vesting of shares of common stock subject to repurchase | 4,317 | — | 3 | — | — | 3 |
| Stock-based compensation | — | — | 6,422 | — | — | 6,422 |
| Unrealized loss on marketable securities, net | — | — | — | (82) | — | (82) |
| Net loss | — | — | — | — | (28,147) | (28,147) |
| Balance at March 31, 2025 | 53,089,957 | $5 | $602,299 | $688 | $(279,458) | $323,534 |
| Common Stock · Additional Paid-In Capital · Accumulated Other Comprehensive Income · AccumulatedDeficit · Total Stockholders’ Equity | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balance at December 31, 2025 | 53,706,357 | $5 | $630,037 | $393 | $(371,258) | $259,177 |
| Issuance of common stock under benefit plans | 1,072,798 | — | 12,289 | — | — | 12,289 |
| Issuance of common stock under at-the-market offering program, net of $2.1 million of issuance costs | 4,690,532 | 1 | 147,852 | — | — | 147,853 |
| Stock-based compensation | — | — | 7,847 | — | — | 7,847 |
| Unrealized loss on marketable securities, net | — | — | — | (286) | — | (286) |
| Net loss | — | — | — | — | (39,305) | (39,305) |
| Balance at March 31, 2026 | 59,469,687 | $6 | $798,025 | $107 | $(410,563) | $387,575 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.